teijin cdmo

What teijin cdmo does

Teijin CDMO is a contract development and manufacturing organization (CDMO) jointly operated by Teijin Regenet Co., Ltd. and Japan Tissue Engineering Co., Ltd. (J-TEC), both wholly-owned subsidiaries of Teijin Group, a diversified Japanese conglomerate. The company provides one-stop CDMO services for cell and gene therapies (CGT) and regenerative medicine, supporting multiple modalities including ex vivo gene-modified cell therapies (CAR-T, NK cells, non-CAR-T), mesenchymal stem cells (MSCs), iPS and ES cells, and tissue-engineered products. Operations span three domestic facilities — the Kashiwanoha Facility (CDO hub in Chiba, operational since February 2024), the Iwakuni Factory (CMO hub in Yamaguchi, operational since August 2023 and in full-scale operation from March 2026), and J-TEC's Gamagori plant in Aichi (operational since 1999) — supplemented by overseas partnerships in Singapore, the United States, and Australia for global clinical and manufacturing support.

The service portfolio covers the full product lifecycle: development consulting, manufacturing process development, clinical trial manufacturing, commercial manufacturing, technology transfer, product specification design support, vector manufacturing via TFBS Bioscience partnership, and comprehensive quality testing (sterility, endotoxin, mycoplasma, human virus, cell purity, potency, stability). A differentiated 'Beyond CDMO' offering extends beyond manufacturing to provide regulatory affairs support, business development assistance, and MAH (Marketing Authorization Holder) matching. The Co-Trial Lab service at Kashiwanoha offers concierge-style early-stage development support. All manufacturing operations operate under GCTP (Good Gene, Cellular, and Tissue-based Products) compliance.

The business operates on a project-by-project B2B contract model with no publicly disclosed pricing tiers, serving three primary customer segments: pharmaceutical and biotech companies developing CGT&RM products (primary), regenerative medicine startups and bio-ventures seeking accelerated Japanese market entry, and academic research institutions translating research into commercial therapies. As of November 2025, the company had achieved 5 regulatory approvals for regenerative medicine products, anchoring a regulatory track record difficult to replicate under Japan's unique PMD Act framework, which provides conditional approval pathways, the Sakigake Designation System, Standards for Biological Ingredients (SBI), and Cartagena Act oversight.

Name

teijin cdmo

Legal name

Teijin Limited

Website

https://teijin-cdmo.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Teijin CDMO is a Japanese cell and gene therapy and regenerative medicine contract manufacturer jointly operated by Teijin Regenet and J-TEC under Teijin Group. It provides one-stop CDMO services across CAR-T, iPS, MSC, and tissue-engineered modalities to pharmaceutical, biotech, and academic clients.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Development and Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA)

akta.pro secondary industries

Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB), Cell Therapy CDMO (HLAGABAD)

Keywords

• Cell therapy manufacturing
• Regenerative medicine CDMO
• Gene therapy services
• Contract development manufacturing
• Biopharmaceutical CDMO

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. CDMO Manufacturing Services: Contract development and manufacturing services for cell & gene therapies and regenerative medicine products, covering clinical trial product manufacturing, commercial manufacturing, and technology transfer. Revenue is generated through project-based contracts with pharmaceutical and biotech clients.
2. Research and Development Consulting: R&D consulting including development plan formulation, PMDA consultation support, and Japan regulatory consulting for foreign companies. Also includes overseas company-oriented Japan regulatory consulting.
3. Quality Testing Services: Comprehensive quality testing services for regenerative medicine products including sterility, endotoxin, mycoplasma, potency, and stability testing, billed as part of the manufacturing or as standalone services.
4. Beyond CDMO - Commercialization Support: Beyond standard manufacturing, provides commercialization support including regulatory affairs, business development support, and MAH (Marketing Authorization Holder) matching, adding advisory fees to core manufacturing revenue.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

Teijin CDMO operates as a joint Contract Development and Manufacturing Organization combining Teijin Regenet Co., Ltd. and Japan Tissue Engineering Co., Ltd. (J-TEC), both subsidiaries of Teijin Group. The company provides contract development and manufacturing services for cell, gene, and regenerative medicine therapies to pharmaceutical and biotechnology clients. Teijin CDMO was formally established in 2023, building on J-TEC's heritage dating to its founding in 1999.

Product overview

TEIJIN CDMO is a unified CDMO (Contract Development and Manufacturing Organization) jointly operated by Teijin Regenet Co., Ltd. and Japan Tissue Engineering Co., Ltd. (J-TEC). The company offers a comprehensive one-stop solution for cell & gene therapy and regenerative medicine, covering the entire product lifecycle from early-stage development through commercial manufacturing. The portfolio includes three domestic manufacturing facilities (Kashiwanoha Facility, Iwakuni Factory, and J-TEC), development consulting services, clinical and commercial manufacturing services, Co-Trial Lab services, and Beyond CDMO support including regulatory affairs and business development. The company supports multiple modalities including CAR-T, iPS cells, and MSCs, with accomplishments of 5 regulatory approvals in regenerative medicine as of November 2025.

Differentiator

Problem solved

Functional benefit

Brands

• Kashiwanoha Facility: CDO (Contract Development Organization) base in Kashiwanoha, Chiba Prefecture - focuses on research, development, and investigational drug manufacturing for regenerative medicine products
• Iwakuni Factory
• Co-Trial Lab

Products and services

• Cell Therapy CDMO Services
• Gene Therapy CDMO Services
• Regenerative Medicine CDMO Services

Quantifiable outcome

• 5 regenerative medicine product approvals achieved (as of November 2025)
• +1 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

15 partnerships are on record, tiered core and minor.

• URAT Co., Ltd. (India)coreStrategic or Co-development Partner · 13 November 2025TEIJIN and URAT (India) entered into a business partnership to expand the regenerative medicine and implantable medical device domain in Japan and India. The partnership leverages URAT's presence in the Indian market for cross-border regenerative medicine business development.
• AlliedCel Pte. Ltd.minorStrategic or Co-development Partner · 28 October 2025J-TEC entered into a business consignment contract with AlliedCel for commercial production of a development product. AlliedCel provides the product, and J-TEC provides manufacturing services.
• Cell Therapies Pty Ltd (Australia)coreStrategic or Co-development Partner · 1 October 2025TEIJIN and Cell Therapies formed a business alliance to accelerate access to CGT therapies across the Asia-Pacific region. The partnership combines TEIJIN's Japanese CDMO capabilities with Cell Therapies' Australian manufacturing and development infrastructure to create a cross-border CGT development and manufacturing network.
• Kerry Japan Co., Ltd.minorStrategic or Co-development Partner · 2 September 2025J-TEC co-presented at INTERPHEX Week 2025 Regenerative Medicine EXPO alongside Kerry Japan on the topic of raw material management for regenerative medicine products, demonstrating an active partnership in the regenerative medicine ecosystem.
• TOHO Holdings Co., Ltd.coreStrategic or Co-development Partner · 10 July 2025TEIJIN REGENET, TOHO Holdings, and ITOCHU Corporation entered into a business partnership contract to build a 'Regenerative Medicine Ecosystem.' The three companies, each with strengths in different service areas required for bringing regenerative medicine products to market, provide one-stop development support services to help bio-venture companies efficiently bring products to market early. TOHO Holdings contributes pharmaceutical distribution and medical institution network expertise.
• ITOCHU CorporationcoreStrategic or Co-development Partner · 10 July 2025TEIJIN REGENET, TOHO Holdings, and ITOCHU Corporation entered into a business partnership contract to build a 'Regenerative Medicine Ecosystem.' ITOCHU contributes its trading company network and international business capabilities to support global expansion of regenerative medicine products developed through the ecosystem.
• Toyohashi University of Technology (Toyohashi Kagaku Daigaku)minorStrategic or Co-development Partner · 15 April 2025J-TEC and Toyohashi University of Technology signed an agreement for comprehensive collaboration, including joint research, industry-academia collaboration, and talent exchange in the regenerative medicine field.
• Sysmex CorporationminorStrategic or Co-development Partner · 24 March 2025J-TEC and Sysmex entered into a joint research contract regarding sterility testing for regenerative cell medicine. The partnership focuses on developing alternative methods to animal testing for sterility assessment.
• Metcela Inc.minorStrategic or Co-development Partner · 26 February 2025J-TEC contracted with Metcela to manufacture clinical trial products for a regenerative medicine product targeting pediatric congenital heart disease. Metcela is the sponsor, and J-TEC provides clinical trial product manufacturing services.
• VC Cell Therapy Inc.minorStrategic or Co-development Partner · 14 January 2025J-TEC entered into a capital and business alliance with VC Cell Therapy for the practical application of iPS cell-based regenerative medicine products. The partnership involves equity investment and joint development of iPS cell-based therapies.
• Mitsui Link-Lab (Mitsui Fudosan)minorStrategic or Co-development Partner · 13 December 2024Partnership through the Kashiwanoha Regenerative Medicine Platform. Mitsui Fudosan's Mitsui Link-Lab facility houses the Kashiwanoha Facility, and the platform includes National Cancer Center and J-TEC as ecosystem participants, supporting innovative regenerative medicine seed development.
• Hillman Lab (Hillman Lab Laboratories)coreStrategic or Co-development Partner · 31 October 2024TEIJIN and Hillman Lab agreed on a strategic business partnership for regenerative medicine CDMO services. Hillman Lab contributes specialized laboratory capabilities to support the partnership's regenerative medicine service offering.
• A-SEEDS Co., Ltd.coreStrategic or Co-development Partner · 31 May 2024TEIJIN REGENET and A-SEEDS signed a memorandum of understanding for the development of a new CAR-T product. A-SEEDS brings novel CAR-T technology, and TEIJIN REGENET provides CDMO manufacturing and development support for the product.
• International CDMO PartnerscoreStrategic or Co-development Partner · 21 April 2023TEIJIN agreed on international CDMO business partnerships as a step toward becoming a global bridge for regenerative medicine CDMO. The partnerships enable cross-border development and manufacturing services for CGT therapies.
• TFBS Bioscience Inc. (Japan)coreTechnology or IntegrationTFBS Bioscience provides vector manufacturing and CRO services (pharmacology, toxicity testing, cell bank characterization, virus clearance testing) under partnership with TEIJIN CDMO, extending the service portfolio to include comprehensive preclinical and vector-related testing.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Pharmaron: China-headquartered CRO/CDMO with growing cell and gene therapy manufacturing services. Pharmaron competes with TEIJIN CDMO particularly for Asia-Pacific CGT clients and offers integrated discovery-to-manufacturing capabilities.
• RoslinCT: Scotland-based cell therapy CDMO specializing in iPS cell and allogeneic cell therapy manufacturing. RoslinCT competes with TEIJIN CDMO for regenerative medicine CDMO contracts and shares the iPS cell modality focus.

Broad incumbents

• Thermo Fisher Scientific (Patheon): Diversified life sciences giant offering pharmaceutical CDMO services through its Patheon brand, plus cell and gene therapy capabilities via Brammer Bio. Competes with TEIJIN CDMO across multiple service categories but as part of a much broader portfolio.

Direct peers

• Catalent (Novo Holdings): Major pharmaceutical CDMO with growing cell and gene therapy capabilities, including viral vector and cell therapy manufacturing. Catalent competes with TEIJIN CDMO for gene-modified cell therapy projects and offers broader global capacity.
• Cell Therapies Pty Ltd: Australian CGT contract development and manufacturing organization that is both a partner and direct competitor to TEIJIN CDMO in the Asia-Pacific region. Cell Therapies serves autologous and allogeneic cell therapy developers with GMP manufacturing capabilities.
• AGC Biologics: Japan-origin biologics and cell/gene therapy CDMO with global manufacturing sites. AGC Biologics is a particularly close peer given shared Japanese heritage and overlapping CGT capabilities including the recently acquired Vibalogics viral vector business.
• Samsung Biologics: Large-scale biologics CDMO expanding into cell and gene therapy services. Samsung Biologics competes with TEIJIN CDMO in the Asia-Pacific region for advanced therapy manufacturing contracts from multinational biopharma.
• WuXi Advanced Therapies: Cell and gene therapy CDMO unit of WuXi AppTec with end-to-end capabilities including viral vector, cell therapy, and plasmid DNA manufacturing. Competes with TEIJIN CDMO for global CGT outsourcing projects, particularly those involving Asian clinical trial manufacturing.
• Charles River Laboratories: CRO/CDMO with significant cell and gene therapy manufacturing services through its Cell Solutions business. Charles River competes with TEIJIN CDMO in CGT process development, viral vector production, and cell therapy manufacturing.
• Lonza: Global leader in cell and gene therapy CDMO services with extensive commercial-scale manufacturing capacity across multiple continents. Lonza competes directly with TEIJIN CDMO for CGT outsourcing contracts from pharmaceutical and biotech clients, particularly in autologous and allogeneic cell therapy manufacturing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/teijin-cdmo

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about teijin cdmo